OBETICHOLIC ACID
Information current as at: 1 April 2026
PBAC meeting date: November 2020
Submission Details
- Brand name:
-
- Ocaliva®
- Form and strength:
- Please search for and view the medicine's Public Summary Document (PSD) for more information
- Condition/indication:
(therapeutic use) -
- Primary biliary cholangitis
- Listing requested:
- Please see PSD for more information
- Funding program:
- Please see PSD for more information
- Request authority level:
- Please see PSD for more information
- PBAC submission type:
- New listing (Major submission)
- Comment:
- --
- Submission sponsor:
- Chiesi Australia Pty Ltd
- Other PBAC consideration:
Progress Details
-
Submission received for: - November 2020 PBAC meeting
-
Opportunity for consumer comment: - Open 26/08/2020 and close 07/10/2020 (see PBS Website)
-
PBAC meeting: - Held on 04/11/2020
-
PBAC outcome published: - Deferred (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
PBAC Outcome
Case ID: a257
Page last updated: 31 March 2026

